Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab plus CyBorD vs CyBorD in newly diagnosed systemic AL amyloidosis
jRCT2080223872Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 4, randomised trial of daratumumab in light-chain amyloidosis (2 arms), sponsored by Janssen Pharmaceutical. Started Apr 2018; status: completed.
02
Drugs
daratumumab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on jRCT2080223872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223872.